AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript

SA Transcripts 161.91K Followers Follow AVITA Medical, Inc. ( RCEL ) Shareholder/Analyst Call August 18, 2026 4:30 PM EDT Company Participants Ben Atkins - Vice President of Investor Relations & Corporate Communications Katie Bush - Senior Vice President of Scientific & Medical Affairs Conference Call Participants Anju Bakshi Saraswat Christina Sharon Joshua Jennings - TD Cowen, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the PermeaDerm KOL webinar. [Operator Instructions] I would now like to hand the conference over to your speaker today, Ben Atkins, Vice President of Investor Relations at AVITA. Ben Atkins Vice President of Investor Relations & Corporate Communications Thank you, and welcome to the AVITA Medical PermeaDerm Key Opinion Leader webinar. Today, we will be reviewing data and cases from our PermeaDerm-I study, which evaluated PermeaDerm as a wound temporizer compared with cadaveric allograft. Before we begin, I'd like to remind you that today's call will include forward-looking statements regarding AVITA's current expectations about future events. Please refer to Slide 3 for additional details. I should also like to add that this presentation will include images of burns and wounds. It's now my pleasure to hand over to Katie Bush, AVITA Medical Senior Vice President of Scientific and Medical Affairs. Katie Bush Senior Vice President of Scientific & Medical Affairs Thank you, Ben. Today's discussion will focus on our PermeaDerm-I clinical study readout and 2 surgeons clinical experience with the product as part of our broader AVITA portfolio. Joining us today are Dr. Anju Saraswat, Assistant Professor of Surgery at Wake Forest University School of Medicine; and Assistant Medical Director of the Atrium Health Wake Forest Baptist Burn Center. Also, Dr. Christina Sharon, a Burn and Acute Care Surgeon and the Burn Director at Baton Rouge General in Louisiana. In a moment, Dr. Saraswat will provide an overview of our clinical trial results, then Dr. Sharon will provide her experience using PermeaDerm as